Avid Bioservices   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Clarence NY United States (1998)

Organization Overview

First Clinical Trial
2000
NCT00004017
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Astrocytoma (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Central Nervous System Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 1)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

HIV Infections (Phase 1)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 2)

Nervous System Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 11